Facing the world, laying out the world | Keyuan Pharma appeared at CPHI Japan 2024!
Recently, 2024 CPHI opened grandly in Tokyo, Japan. As one of the vanes in the global pharmaceutical industry, CPHI attracts pharmaceutical companies, scientific research institutions and industry experts from all over the world every year to discuss the latest development trends and technological innovations in the pharmaceutical industry.
As a leading company in the Chinese API segment, Keyuan Pharma (stock code: 301281.SZ) appeared at this exhibition with its excellent quality, cutting-edge R&D strength, and digital intelligent manufacturing capabilities, successfully attracting the attention of the global industry. Jianwei Wang, President of Keyuan Pharma, led the team to talk about friendship and business with new and old customers from all over the world ,to further deepen future market expansion and business cooperation.
This exhibition not only demonstrates Keyuan Pharma' competitiveness in the international market, but is also an important step in company’s global strategic layout. In recent years, Keyuan Pharma' internationalization has been accelerating. Under the guidance of the "one body, two wings and three pillars" development strategy, Keyuan Pharma focuses on the field of chronic diseases, actively expands other characteristic market segments, deepens the unique advantages of API and finished products integration, excipient and finished products integration, strengthens technology research and development, promotes digital intelligent manufacturing, and implements cultural marketing. Keyuan Pharma's partners have spread across dozens of countries and regions around the world, forming a global marketing network.
As the 2024 CPHI (Japan) exhibition progresses, Keyuan Pharma will continue to demonstrate the strength and style of Chinese pharmaceutical companies with its outstanding performance. In the future, Keyuan Pharma will continue to participate in top international exhibitions, further broaden its international vision, enhance communication and cooperation with international partners, and contribute to the common development of the global pharmaceutical industry.